SCOPUS 정보 검색 플랫폼

Neurology

Volumn 82, Issue 4, 2014, Pages 288-289

Amantadine's role in the treatment of levodopa-induced dyskinesia

(2) Rodnitzky, Robert L a Narayanan, Nandakumar S a

a UNIVERSITY OF IOWA (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LEVODOPA; PLACEBO;

CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSKINESIA; EDITORIAL; FOOT EDEMA; HUMAN; LEVODOPA INDUCED DYSKINESIA; LIVEDO RETICULARIS; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

AMANTADINE; ANTIPARKINSON AGENTS; ANTIVIRAL AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84895748279 PISSN: 00283878 EISSN: 1526632X Source Type: Journal
DOI: 10.1212/WNL.0000000000000068 Document Type: Editorial

Times cited : (23)

References (8)

1
- 14944354884
- Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years
- Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years.Mov Disord 2005;2:190-199.
- (2005) Mov Disord , vol.2 , pp. 190-199
- Hely, M.A.¹ Morris, J.G.² Reid, W.G.³ Trafficante, R.⁴

2
- 80055083817
- The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of parkinson's disease
- Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(suppl 3):S2-S41.
- (2011) Mov Disord , vol.26 , Issue.SUPPL. 3
- Fox, S.H.¹ Katzenschlager, R.² Lim, S.Y.³

3
- 84855193194
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
- Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 2011; 118:1661-1690.
- (2011) J Neural Transm , vol.118 , pp. 1661-1690
- Iravani, M.M.¹ Jenner, P.²

4
- 19944427055
- Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia
- Aubert I, Guigoni C, Håkansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.
- (2005) Ann Neurol , vol.57 , pp. 17-26
- Aubert, I.¹ Guigoni, C.² Håkansson, K.³

5
- 50049087567
- Molecular mechanisms of L-DOPA-induced dyskinesia
- Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-677.
- (2008) Nat Rev Neurosci , vol.9 , pp. 665-677
- Jenner, P.¹

6
- 0345863897
- Duration of amantadine benefit on dyskinesia of severe Parkinson's disease
- Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatr 2004;75:141-143.
- (2004) J Neurol Neurosurg Psychiatr , vol.75 , pp. 141-143
- Thomas, A.¹ Iacono, D.² Luciano, A.L.³ Armellino, K.⁴ Di Iorio, A.⁵ Onofrj, M.⁶

7
- 84894662888
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 2014;82:300-307.
- (2014) Neurology , vol.82 , pp. 300-307
- Ory-Magne, F.¹ Corvol, J.C.² Azulay, J.P.³

8
- 84875542011
- Which dyskinesia scale best detects treatment response?
- Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-346.
- (2013) Mov Disord , vol.28 , pp. 341-346
- Goetz, C.G.¹ Stebbins, G.T.² Chung, K.A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.